Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $7,665 | $10,348 | $6,795 | $121 |
| % Growth | -25.9% | 52.3% | 5,536.3% | – |
| Cost of Goods Sold | $3,760 | $4,335 | $321 | $361 |
| Gross Profit | $3,904 | $6,013 | $6,474 | -$240 |
| % Margin | 50.9% | 58.1% | 95.3% | -199.5% |
| R&D Expenses | $753 | $1,281 | $706 | $3,109 |
| G&A Expenses | $10,217 | $1,361 | $2,181 | $4,158 |
| SG&A Expenses | $12,827 | $10,798 | $4,066 | $5,278 |
| Sales & Mktg Exp. | $2,609 | $2,948 | $1,885 | $1,120 |
| Other Operating Expenses | $2,535 | $46 | -$1,486 | $116 |
| Operating Expenses | $16,115 | $18,113 | $3,110 | $7,002 |
| Operating Income | -$12,210 | -$10,416 | -$7,544 | -$7,422 |
| % Margin | -159.3% | -100.7% | -111% | -6,156.2% |
| Other Income/Exp. Net | $193 | -$1,493 | -$2,352 | $344 |
| Pre-Tax Income | -$12,017 | -$11,909 | -$7,163 | -$7,078 |
| Tax Expense | $0 | -$158 | -$32 | $0 |
| Net Income | -$12,017 | -$11,751 | -$7,131 | -$7,078 |
| % Margin | -156.8% | -113.6% | -104.9% | -5,870.9% |
| EPS | -2.73 | -3.6 | -2.32 | -2.48 |
| % Growth | 24.2% | -55.2% | 6.5% | – |
| EPS Diluted | -2.73 | -3.6 | -2.32 | -2.48 |
| Weighted Avg Shares Out | 4,612 | 3,379 | 3,073 | 2,848 |
| Weighted Avg Shares Out Dil | 4,612 | 3,379 | 3,073 | 2,848 |
| Supplemental Information | – | – | – | – |
| Interest Income | $120 | $220 | $36 | $62 |
| Interest Expense | $52 | $30 | $15 | $14 |
| Depreciation & Amortization | $535 | $677 | $579 | $478 |
| EBITDA | -$11,431 | -$11,203 | -$7,201 | -$6,583 |
| % Margin | -149.1% | -108.3% | -106% | -5,460.7% |